Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06852820 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date: Sep 22, 2025 to Jun 2026 · Site details revisedv6 Show 2 more changesShow less
    • Start date: Sep 22, 2025 to Jun 2026
    • Site details revised
  2. Start date: Sep 2025 to Sep 22, 2025v5
  3. Start date: Jun 2025 to Sep 2025v4
  4. Start date: Apr 1, 2025 to Jun 2025v3
  5. Primary endpoints revised (2) Study description shortened, about 1 wordv2 Show 1 more changeShow less
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Melissa Lumish
2 trials monitored
See 1 trial at risk
Liver Cancer
1,512 trials monitored
See 63 trials at risk
The purpose of this study is to look at the effects (good and bad) of a drug called 177Lu-PSMA-617 (also known as the study drug) when given to participants who have prostate specific membrane antigen (PSMA) positive liver cancer.
Trial Details
NCT Number NCT06852820
Lead Sponsor Melissa Lumish
Collaborators: Novartis
Conditions Liver Cancer, Hepatocellular Carcinoma, Metastatic Liver Cancer
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov